3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Autophagy Upregulates miR-449a Expression to Suppress Progression of Colorectal Cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Many studies reported that microRNAs (miRNAs) target autophagy-related genes to affect carcinogenesis, however, autophagy-deficiency-related miRNA dysfunction in cancer development remains poorly explored. During autophagic progression, we identified miR-449a as the most up-regulated miRNA. MiR-449a expression was low in the tumor parts of CRC patient specimens and inversely correlated with tumor stage and metastasis with the AUC (area under the curve) of 0.899 and 0.736 as well as poor overall survival rate, indicating that miR-449a has the potential to be a prognostic biomarker. In the same group of CRC specimens, low autophagic activity (low Beclin 1 expression and high p62 accumulation) was detected, which was significantly associated with miR-449a expression. Mechanistic studies disclosed that autophagy upregulates miR-449a expression through degradation of the coactivator p300 protein which acetylates the transcription factor Forkhead Box O1 (FoxO1). Unacetylated FoxO1 translocated to the nucleus and bound to the miR-449a promoter to drive gene expression. Either activation of autophagy by the inducer or overexpression of exogenous miR-449a decreases the expression of target gene LEF-1 and cyclin D1, which lead to decreased proliferation, colony formation, migration, and invasion of CRC cells. Autophagy-miR-449a-tartet genes mediated suppression of tumor formation was further confirmed in the xenograft mouse model. In conclusion, this study reveals a novel mechanism wherein autophagy utilizes miR-449a-LEF1-cyclin D1 axis to suppress CRC tumorigenesis. Our findings open a new avenue toward prognosis and treatment of CRC patients by manipulating autophagy-miR-449a axis.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses1

            Genomics data from The Cancer Genome Atlas (TCGA) project has led to the comprehensive molecular characterization of multiple cancer types. The large sample numbers in TCGA offer an excellent opportunity to address questions associated with tumo heterogeneity. Exploration of the data by cancer researchers and clinicians is imperative to unearth novel therapeutic/diagnostic biomarkers. Various computational tools have been developed to aid researchers in carrying out specific TCGA data analyses; however there is need for resources to facilitate the study of gene expression variations and survival associations across tumors. Here, we report UALCAN, an easy to use, interactive web-portal to perform to in-depth analyses of TCGA gene expression data. UALCAN uses TCGA level 3 RNA-seq and clinical data from 31 cancer types. The portal's user-friendly features allow to perform: 1) analyze relative expression of a query gene(s) across tumor and normal samples, as well as in various tumor sub-groups based on individual cancer stages, tumor grade, race, body weight or other clinicopathologic features, 2) estimate the effect of gene expression level and clinicopathologic features on patient survival; and 3) identify the top over- and under-expressed (up and down-regulated) genes in individual cancer types. This resource serves as a platform for in silico validation of target genes and for identifying tumor sub-group specific candidate biomarkers. Thus, UALCAN web-portal could be extremely helpful in accelerating cancer research. UALCAN is publicly available at http://ualcan.path.uab.edu.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Autophagy in health and disease: A comprehensive review.

              Autophagy, a conserved catabolic process, plays an immensely significant role in a variety of diseases. However, whether it imparts a protective function in diseases remains debatable. During aging, autophagy gradually subsides, manifested by the reduced formation of autophagic vacuoles and improper fusion of these vacuoles with the lysosomes. Similarly, in neurodegenerative disorders, accumulation of tau and synuclein proteins has been attributed to the decline in the autophagic removal of proteins. Equivalently, lysosomal disorders show an impairment of the autophagic process leading to the accumulation of lipid molecules within lysosomes. On the other hand, activation of the autophagic pathway has also proved beneficial in evading various foreign pathogens, thereby contributing to the innate immunity. In the context of cancer, autophagy has shown to play a puzzling role where it serves as a tumor suppressor during initial stages but later protects the tumor cells from the immune system defense mechanisms. Similarly, muscular and heart disorders have been shown to be positively and negatively regulated by autophagy, respectively. In the present review, we, therefore, present a comprehensive review on the role of autophagy in various diseases and their corresponding outcomes.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                19 October 2021
                2021
                : 11
                : 738144
                Affiliations
                [1] 1 Department of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University , Taipei, Taiwan
                [2] 2 Cancer Progression Research Center, National Yang Ming Chiao Tung University , Taipei, Taiwan
                [3] 3 Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University , Tainan, Taiwan
                [4] 4 Department of Surgery, College of Medicine, National Cheng Kung University Hospital , Tainan, Taiwan
                [5] 5 Center for Cancer Research, Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University , Kaohsiung, Taiwan
                [6] 6 Department of Gastroenterology, Hospital Centro Médico , Guatemala City, Guatemala
                [7] 7 Master of Science Program in Tropical Medicine, College of Medicine, Kaohsiung Medical University , Kaohsiung, Taiwan
                [8] 8 Department of Microbiology and Immunology, College of Medicine, Taipei Medical University , Taipei, Taiwan
                [9] 9 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University , Taipei, Taiwan
                Author notes

                Edited by: Shuyun Rao, Feinstein Institute for Medical Research, United States

                Reviewed by: Suraj Kadunganattil, Amala Cancer Research Centre, India; Chuanxin Wang, Second Hospital of Shandong University, China

                *Correspondence: Hsiao-Sheng Liu, hsliu713@ 123456kmu.edu.tw ; Shan-Ying Wu, shanyingwu@ 123456tmu.edu.tw

                This article was submitted to Gastrointestinal Cancers: Colorectal Cancer, a section of the journal Frontiers in Oncology

                Article
                10.3389/fonc.2021.738144
                8560741
                34737955
                4668534c-b519-484e-9272-6629a7703d94
                Copyright © 2021 Lan, Lin, Wang, Yang, Lee, Lin, Chu, Lan, Zuchini, Liu and Wu

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 08 July 2021
                : 04 October 2021
                Page count
                Figures: 6, Tables: 0, Equations: 0, References: 47, Pages: 13, Words: 6552
                Funding
                Funded by: Ministry of Science and Technology, Taiwan , doi 10.13039/501100004663;
                Award ID: MOST 109-2314-B-038-119-MY2, MOST 104-2320-B-006-021-MY3
                Funded by: Taipei Medical University , doi 10.13039/501100004700;
                Award ID: TMU108-AE1-B39
                Funded by: Ministry of Health and Welfare , doi 10.13039/501100003625;
                Award ID: MOHW 106-TDU-B-211-124-003
                Funded by: Kaohsiung Medical University , doi 10.13039/501100004694;
                Award ID: KMU-TC108A04-0, KMU-TC108A04-2, KMU-TC109A04-1
                Categories
                Oncology
                Original Research

                Oncology & Radiotherapy
                autophagy,mir-449a,foxo1,colorectal cancer,tumorigenesis
                Oncology & Radiotherapy
                autophagy, mir-449a, foxo1, colorectal cancer, tumorigenesis

                Comments

                Comment on this article